The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer
Eligible age
21+ yrs
Accepts
Women
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of the SENTRY (Stability Enhanced Transcriptional Analytics) Study is to test whether combining a unique analytical approach with changes in platelet RNA expression accurately diagnoses ovarian cancer. Using retrospective data, the investigators have developed an approach that appears to accurately classify ovarian cancer with relatively high sensitivity and specificity. The SENTRY Study will build upon these retrospective analyses to prospectively recruit women with ovarian cancer or an ovarian mass (and healthy control women), obtain platelet RNA samples from whole blood, and perform validation analyses to test our hypothesis.
Sponsor: University of Utah
You may qualify if…
- ✓ 1. Women aged 21 years or older
- ✓ 2. Diagnosed with any type of ovarian or pelvic mass
- ✓ 3. Treatment naïve for current ovarian cancer (if cancer has been diagnosed)
- ✓ 4. The treating medical provider(s) are planning to perform a biopsy, surgery, or other diagnostic procedure to further evaluate the ovarian or pelvic mass (if not already diagnosed prior to consent)
- ✓ 1\. Women aged 21 years or older
You may not qualify if…
- ✕ 1. Any other active malignancy
- ✕ 2. Other diagnosis of any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix
- ✕ 3. Treatment for any cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix. Adjuvant endocrine therapy or other maintenance therapy is allowed.
- ✕ 4. Currently receiving chemotherapy, radiation therapy, or other treatments for ovarian cancer
- ✕ 5. Has already undergone complete ovarian mass resection
- ✕ 6. Unable to provide blood sample
- ✕ Study Population 3: Control Women without Ovarian Cancer (n=30)
- ✕ 1. Any active malignancy or diagnosis of cancer within the last 6 months except for non-melanoma skin cancer or carcinoma in situ of the cervix
Where it's recruiting
Salt Lake City
Source: ClinicalTrials.gov · NCT06665945 · last updated 2026-04-09